LIMNW 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-14

• On June 3, 2026, we entered into a warrant exercise inducement offer letter (the “Inducement Letter Agreement”) with a holder of our existing common stock warrants exercisable for an aggregate of 10,344,000 shares of our common stock (collectively, the “Existing Warrants”), to exercise its Existing …

• from the exercise of the Existing Warrants is approximately $1,861,921, before deducting financial advisory fees. The fair value of the Inducement Warrants was $2,211,295 at inducement, or $0.18 per instrument.

• In connection with the transaction described above, we entered into a financial advisory services agreement, dated June 3, 2026, with Maxim, pursuant to which we agreed to pay Maxim for its services a cash fee of up to 8% of the gross proceeds received by us in connection with the exercise of the Ex…

• The Warrant Inducement, which resulted in the issuance of the Company’s common stock in exchange for the cash exercise of the Existing Warrants, is considered a modification of the Existing Warrants under the guidance of ASC 815-40. The modification is consistent with the “Equity Issuance” classific…

• On May 17, 2026, we entered into a Merger Agreement (the “Original Merger Agreement”) with InnocsAI LLC, a Delaware limited liability company (“InnocsAI”), and NamChul Jung, in his capacity as the representative of the members of InnocsAI. Under the Original Merger Agreement, the aggregate considera…

相对上期删除的文字 · 来源:10-Q · 2026-05-15

• Comparison of the Three Months Ended March 31, 2026 and 2025

• The following is a comparative of our results of operations for the three months ended March 31, 2026 and 2025:

• General and administrative expenses consists primarily of professional service fees, including accounting and legal services and other general operating expenses. General and administrative expenses increased by $436,678 during the three months ended March 31, 2026 as compared to the three months en…

• Research and development expenses consist of costs incurred by InnoBation Bio Co, Ltd. (“Innobation”) who was performing the research and development activities for the Company in accordance with the license agreements with Innobation. Research and development expenses increased by $400,000 as a res…

• The other expense, net decreased by $40,490 from $63,306 of other expense for the three months ended March 31, 2025 to $22,816 of other expense for the three months ended March 31, 2026. The Company recognized interest expense of $18,638 on related party promissory notes during the three months ende…